2-Day Virtual Seminar

PV (Pharmacovigilance) Audit Strategy Planning - A Practical Approach to Design and Implementation

BY: Cynthia Brysch, Senior Principal Consultant, Oxenham Group

Virtual Training Through WebEx
Various parts of the country are still battling the Coronavirus (COVID-19), we will conduct the class 100% online.

November 18-19, 2021
(9:30 AM to 4:30 PM EST)
Virtual Seminar
  • Course Description
  • Agenda
  • Speaker
  • Price/Register

European Medicines Agency's (EMA) Guideline on good pharmacovigilance practices (GVP), Module IV requires that risk-based audits of the quality system be performed at regular intervals to assure that it complies with the established quality requirements and to determine its effectiveness. It includes audit of the pharmacovigilance system which is covered by the quality system. The GVP Modules are applicable to EU-based companies and any company marketing medicinal products on a global basis. The legally required risk-based audit strategy has to cover all PV processes and tasks undertaken by or delegated to other departments, Marketing Authorization Holder affiliates, and third parties such as distributors, external service providers, licensing partners. In other words, has to cover all PV Universe. The PV Audit Strategy Plan is used to prepare the PV audit program, i.e. annual PV Audit Schedule. Using risk-based approach to develop an audit strategy, companies can conform to the regulatory requirements and business needs. But the questions remain: How to do it? Where to start? How to improve? What are the best industry practices?

In this two day workshop, we will review the legal GVP requirements (predominantly European, FDA and Arab League) regarding risk-based audits of the PV system and quality system. The course will focus on:

  • The design of the PV audit strategy and tactical PV audit plan/schedule.
  • Identification of the PV processes and entities subject to PV audit (understanding how to define the PV audit universe)
  • Development of risk assessment methodology for various aspects of PV world (for instance computerized systems, market research, patient support programmes, vendors, processes etc)
  • Development of procedures/tools to monitor PV processes and activities, and implementation of the PV audit strategy plan.
Learning Objectives:

Upon completing of this course, participants should be able to:

  • Understand the legal requirements and health authority expectations for a risk based audit program and current interpretation.
  • Plan, develop and implement the PV Audit Strategy Plan, which includes the following processes:
    • Identify the PV activities and processes subject to PV audit
    • Identify the PV audit universe – entities subject to PV audit
    • Categorize the entities subject to PV audit
    • Develop risk assessment criteria specific to PV areas
    • Perform risk assessments
    • Develop a high-level PV audit strategy
    • Prioritize entities for audit according to relative risk
    • Prepare a 3-5 year PV audit plan
  • Identify procedures/tools to monitor PV quality of third parties
Who will Benefit:

This course is designed for people with some PV experience and tasked with developing, maintaining, updating and/or reviewing the PV quality system audit strategy plan, risk assessment and/or the annual PV audit schedules. It is also beneficial for staff responsible for the quality oversight of third parties conducting PV activities.

The following personnel will benefit from the course:

  • PV Quality Assurance Staff
  • PV Compliance professionals
  • Quality auditors
  • Pharmacovigilance Auditors
  • Relevant Pharmacovigilance Staff
  • PV Service Provider Relationship Managers
  • MAH Affiliates responsible for Pharmacovigilance
Day 01(9:30 AM to 4:30 PM EST)
  • 09.30 AM: Session Start
  • Review of FDA and EMEA requirements for risk based PV audits
  • The pharmacovigilance system and the quality system
  • Strategic level audit planning
  • Hands on exercise
  • PV activities and processes subject to PV audit
  • Risk assessment criteria
  • The PV audit universe - all entities subject to PV audit
  • Safety data exchange agreements (SDEAs) and vendor contracts
Day 02(9:30 AM to 4:30 PM EST)
  • Stability (shelf-life) studies
  • Categorization of the entities (PV Audit Universe)
  • Risk assessments
  • Prioritization of entities for audit according to relative risk
  • 3-5 year PV audit plan
  • Hands on exercise
  • Procedural documents, e.g. SOPs
  • Identify procedures/tools to monitor PV quality for oversight of third parties
  • Q & A
Cynthia Brysch
Cynthia Brysch, Senior Principal Consultant, Oxenham Group

Cynthia is an accomplished executive director and chief compliance officer with over 17 years’ experience providing first-to-market solutions to the challenges sponsor face whilst using risk management strategies to mitigate ones in the future. She is an industry expert with contributions to over 450 sponsor programs with proven track record of optimization, quality, compliance, and fiscal responsibility. Cynthia is a certified Quality Assurance (QA) and Regulatory Affairs (RA) executive, principal consultant and published biotechnologist with an emphasis in fabricating quality-based process and product development strategies in regulated pharmaceutical, medical device and biopharma industries. In her tenure she has lead strategic partnerships to solve the complexities of the life science industry by providing tailored expertise with the time and resources necessary to mitigate the challenges sponsors face with expertly sourced solutions. She drives QBD initiatives into corporate portfolios to which traverse all phases of development and deployment from a financial, operative, quality, and regulatory vantage. As an expert in national and international GxP regulations, standards and guidance's, her expertise has been engaged as an international HA consultant for over 7yrs with support that traverses all product development phases to deploy best in class programs for industry sponsors including, but not limited to, Gilead, Daichi-Sankyo, Bristol Myers Squib, Amgen, Abbott, Novartis, and Roche.

Register Now

Online using Credit card


(One Dial-in One Attendee)

November 18-19, 2021, Virtual Seminar
(Registrations till October 25, 2021 - $1699)
(Registrations after October 25, 2021 - $2299)


Group-Max. 10 Attendees

November 18-19, 2021, Virtual Seminar
(Registrations till October 25, 2021 - $9685)
(Registrations after October 25, 2021 - $10195)

For discounts on multiple registrations, contact customer care at +1-888-771-6965.

Other Registration Options

By order form / PO#

Payment Modes

By Check -

To pay by check please contact customercare@fdatrainingalert.com

By Wire -

Register / Pay by Wire TransferPlease contact us at +1-888-771-6965 to get details of wire transfer option.

Terms & Conditions to Register for the Seminar/Conference/Event »

Terms & Conditions to register for the Seminar/Conference/Event

Your Registration for the seminar is subject to following terms and conditions. If you need any clarification before registering for this seminar please call us @ +1-888-771-6965 or email us @ customercare@fdatrainingalert.com

Payment is required before 2 days of the date of the conference. We accept American Express, Visa and MasterCard. Make checks payable to MetricStream Inc. ( our parent company)

Cancellations and Substitutions:
Written cancellations through fax or email (from the person who has registered for this conference) received at least 10 calendar days prior to the start date of the event will receive a refund — less a $300 administration fee. No cancellations will be accepted — nor refunds issued — within 10 calendar days from the start date of the event.

On request by email or fax (before the seminar) a credit for the amount paid minus administration fees ($300) will be transferred to any future FDATrainingAlert event and a credit note will be issued.

Substitutions may be made at any time. No-shows will be charged the full amount.

We discourage onsite registrations, however if you wish to register onsite payment to happen through credit card immediately or check to be submitted onsite. Conference material will be given on the spot if it is available after distributing to other attendees. In case it is not available we will send the material after the conference is over.

In the event FDATrainingAlert cancels the seminar, FDATrainingAlert is not responsible for any airfare, hotel, other costs or losses incurred by registrants. Some topics and speakers may be subject to change without notice.

Attendance confirmation and Documents to carry to the seminar venue:
After we receive the payment from the registered attendee an electronic event pass will be sent to the email address associated with the registrant before 5 working days from the seminar date. Please bring the pass to the venue of the event.

Conference photograph / video:
By registering and attending FDATrainingAlert conference you agree to have your photographs or videos taken at the conference venue and you do not have any objections to use these photos and videos by FDATrainingAlert for marketing, archiving or any other conference related activities. You agree to release FDATrainingAlert for any kind of claims arising out of copyright or privacy violations.

You Recently Viewed